Synonym: Flagecidin;Wuningmeisu C
Anisomycin is a pyrrolidine antibiotic, which inhibits protein synthesis, and also act as a JNK activator. Anisomycin (3 μM) decreases protein synthesis in MDA16 and MDA-MB-468 cells, and reduces colony formation by MDA-MB-468 cells. Anisomycin causes an increase in the number of apoptotic cells in MDA-MB-468 cultures, but not in MDA16 cultures. In U251 and U87 cells, anisomycin (0.01-8 μM) inhibits the cell growth in time- and concentration-dependent manners with the IC50 (48 h) values of 0.233 and 0.192 μmol/L, respectively. Anisomycin inhibits EAC cell proliferation in concentration-dependent manner. Peritumoral administration of anisomycin (5 mg/kg) significantly suppresses Ehrlich ascites carcinoma (EAC) growth resulting in the survival of approximately 60% of the mice 90 days after EAC inoculation.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 41 mg/mL warmed
Ethanol 17 mg/mL warmed
Inhibition of protein synthesis and JNK activation are not required for cell death induced by anisomycin and anisomycin analogues.
Monaghan D, et al. Biochem Biophys Res Commun. 2014 Jan 10;443(2):761-7. PMID: 24333448.
In vitro and in vivo evaluation of anisomycin against Ehrlich ascites carcinoma.
You P, et al. Oncol Rep. 2013 Jun;29(6):2227-36. PMID: 23525555.
|Related JNK Products|
YS 49 has potential as a therapeutic strategy for the pathogenesis of Ang II-related vascular diseases such as hypertension and atherosclerosis, via the induction of HO-1 gene activity.
|JNK Inhibitor IX
JNK inhibitor IX is a selective and potent JNK inhibitor with pIC50 of 6.5 and 6.7 for JNK2 and JNK3, respectively.
SP600125 is a novel and selective inhibitor of c-Jun N-terminal kinase (JNK), inhibited phosphorylation of c-Jun with an IC50 of 5-10 microM.
JNK-IN-8 is a selective JNK inhibitor that inhibits phosphorylation of c-Jun.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.